Home > Insider Trading > Filing (0000899243-18-020534)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434418	Constellation Pharmaceuticals Inc	CNST	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1180428	J Mark Levin	C/O Third Rock Ventures, Llc 29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1192603	P Kevin Starr	C/O Third Rock Ventures, Llc 29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1408591	Third Rock Ventures Lp	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1578973	Trv Gp, Llc	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1578976	Third Rock Ventures Gp, L.p.	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-07-23	2,705,334	$0.00	2,716,384	No	4	C	Direct
Common Stock	Acquisiton	2018-07-23	266,667	$15.00	2,983,051	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2018-07-23	11,000,000	$0.00	999,180	$0.00
Common Stock	Series B Preferred Stock	Disposition	2018-07-23	10,650,000	$0.00	967,389	$0.00
Common Stock	Series D Preferred Stock	Disposition	2018-07-23	1,086,411	$0.00	98,683	$0.00
Common Stock	Series E Preferred Stock	Disposition	2018-07-23	2,285,640	$0.00	266,934	$0.00
Common Stock	Series E-1 Preferred Stock	Disposition	2018-07-23	3,107,930	$0.00	282,308	$0.00
Common Stock	Series F Preferred Stock	Disposition	2018-07-23	1,000,000	$0.00	90,840	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares